As weight‑loss drugs surge in popularity, a study raises a new question about what patients may be losing along the way.

Researchers at the University of Pennsylvania in Philadelphia have used AI to analyze more than 400,000 Reddit posts and identify potential GLP-1 side effects not fully captured in clinical trials.

Novo Nordisk received 3,071 prescriptions in the first four days after its January 5 U.S. debut. ・Eli Lilly said that ...

Omada Health (Nasdaq: OMDA), the virtual-first provider of between-visit care, announced new study results demonstrating that Omada members in its GLP-1 Care Track lost, on average, 1.8 times more ...

The rivalry between Lilly's tirzepatide and Novo's semaglutide continues as new study finds that tirzepatide leads to greater ...

A physician examines whether the FDA's loosening of wellness peptide restrictions means these compounds are actually safe and ...

Eli Lilly's GLP-1 drug tirzepatide yields greater weight loss on average than Novo Nordisk's semaglutide, but at a greater ...

Doctors say they’ve begun hearing similar accounts of people taking GLP-1 medication feeling a kind of emotional flattening ...

GoodRx reports that GLP-1 medications aid weight loss but often require long-term use to maintain results and prevent weight ...

Discover the top 10 weight loss medications of 2026. Explore how advanced GLP-1 therapies and combination drugs are reshaping ...

Hims & Hers faces key FDA decisions on compounded GLP-1/semaglutide peptides—upside if permitted, downside if restricted.

At the heart of the request is whether taking Foundayo - made with a new active ingredient called orforglipron - could be ...